Vol. 9 No. 1 (2022): January-December 2022

Published: 2022-01-25

Full Issue

Point of View

  • Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

    Anna Maria Marata, Walter Marrocco, Emanuela Arcangeli, Mattia Battistini, Giuliano Buzzetti, Riccardo Candido, Gianluigi Casadei, Francesco Cattel, Arturo Cavaliere, Agostino Consoli, Giovanni Corrao, Guido Didoni, Mauro Di Gesù, Alberto Giovanzana, Matteo Lenzi, Massimo Medaglia, Marta Meloncelli, Stefano Palcic, Marcello Pani, Francesca Patarnello, Emanuele Pria, Dario Scaduto, Valeria Tozzi, Marco Zibellini, Elisa Crovato
    155-158
    DOI: https://doi.org/10.33393/grhta.2022.2495

  • Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

    Francesca Patarnello, Emiliano Briante, Federico Villa
    117-122
    DOI: https://doi.org/10.33393/grhta.2022.2440

  • Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness

    Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, Valentina Acciai, Antonio Addis, Andrea Ardizzoni, Renato Bernardini, Alberto Bortolami, Alessia Brigido, Giuliano Buzzetti, Pier Luigi Canonico, Francesca Caprari, Stefano Centanni, Chiara Cernetti, Americo Cicchetti, Giorgio Corsico, Francesco Damele, Filippo De Braud, Sara Manurita, Francesco Saverio Mennini, Irene Olivi, Federica Parretta, Lara Pippo, Stefania Pulimeno, Massimo Riccaboni, Giuseppe Rossi, Cecilia Saleri, Alessandra Sinibaldi, Federico Spandonaro, Cristian Stefenoni, Elena Visentin, Pierluigi Viale, Giuseppina Zapparelli, Patrizia Popoli
    99-104
    DOI: https://doi.org/10.33393/grhta.2022.2475

  • How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

    Pierluigi Russo
    31-35
    DOI: https://doi.org/10.33393/grhta.2022.2350

Original Research Articles

Short Communication

  • Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

    Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi
    9-13
    DOI: https://doi.org/10.33393/grhta.2022.2331

Erratum